ThermoGenesis to seek stockholder approval for reverse stock split

ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, said today it will seek stockholder approval of an authorization enabling its Board of Directors in its discretion to affect a reverse stock split in the range of one-for-three to one-for-five shares of common stock in the near future, if required to maintain NASDAQ listing. The authorization will be voted upon during a special meeting of stockholders to be held on Monday, August 9th.

The Company said a reverse split may be necessary to enable it to meet the continued listing rules of the NASDAQ Capital Market, and could serve to improve the marketability and liquidity of its common stock.

"We want to have this option, if necessary, available to the Company as we continue to implement our long-term strategy to enhance stockholder value by focusing on the development of enabling technologies for the stem cell regenerative medicine market," said J. Melville Engle, Chief Executive Officer of ThermoGenesis.

In connection with the reverse stock split, ThermoGenesis will file a proxy statement and other materials with the Securities and Exchange Commission. Before making any voting or investment decision, investors are urged to read the proxy statement and these materials when they become available because they will contain important information. ThermoGenesis and its officers and directors may be deemed to be participants in the solicitation of proxies with respect to the proposed reverse stock split. Information regarding such individuals is included in the Company's proxy statements and reports filed with the Securities and Exchange Commission and will be included in the proxy statement relating to the proposed reverse stock split when it becomes available. Stockholder may obtain the ThermoGenesis proxy statement, when it becomes available, any amendments or supplements to the proxy statement and other relevant documents free of charge at www.sec.gov. Stockholder may also obtain a free copy of ThermoGenesis' proxy statement, when it becomes available, any amendments and supplements to the proxy statement and other relevant documents by writing to ThermoGenesis at 2711 Citrus Road, Rancho Cordova, California 95742, Attn: Investor Relations, or at www.thermogenesis.com.